Efficiency, Sustainability Drive Thermo Fisher’s New Microarray Data Analysis Solution
There
are two key things to know about the new Applied
Biosystems™ SwiftArrayStudio™ Microarray Analyzer from Thermo Fisher
Scientific, said Ravi Gupta, vice president and general manager of Thermo
Fisher’s microarray business, in an interview with GEN. It is designed to
be faster, more efficient, and cost-effective than existing tools, while
addressing current research and anticipating future applications. Robert Balog,
PhD, senior director of research and development at Thermo, echoed those
points. Although this first version of the analyzer focuses on genotyping and
copy number variation, there are developments in the roadmap that will “lead us
to other biomarker types and other variant types,” he told GEN.
The
conversation took place during this year’s meeting of the American Society of
Human Genetics in Boston, MA, where Thermo officially launched the device. The
company says that the system integrates four key genotyping processes, allowing
researchers to conduct large-scale genome-wide association studies and make
discoveries in pharmacogenomics.
The
launch reflects broader efforts from Thermo to modernize microarray technology.
Microarrays remain a well established laboratory staple, but even mature
technologies can benefit from upgrades, Gupta noted. “Customers continue to
look for new ways to do things better,” he said. “They want to make sure that
the quality is definitely high and is maintained” while managing cost concerns
and doing more with fewer resources. With the launch of SwiftArrayStudio, “a
lot of my conversations have been around how [the platform] helps our customers
to achieve their goals,” he said.
Some
customers’ needs go beyond efficiency and reliability, Balog pointed out. “They
are asking, ‘how can I do the things that I have to do every day better? How
can I use my staff’s time better? How can I use the equipment I have in the
most efficient way?” And that’s one area where the SwiftArrayStudio shines, he
said. “It’s getting those research customers the ability to do things that they
haven’t been able to do before with this technology.”
Another
benefit of the solution is the time savings. Thermo claims that
SwiftArrayStudio delivers analysis results in as little as 30 hours and reduces
hands-on-time by up to 40 percent compared to previous workflows. These gains
are the result of automating several steps as well as tweaks to speed up data
processing, Balog said.
Because
“we developed [the] solution from the ground up, we were able to [identify]
where we could make the technical trades, whether it was in the assay, the
hardware, and how quickly we scanned the bioinformatics and how we did the
analysis,” he explained. Users can run 96- or 384-well plates depending on
their workflow requirements. “We are able to handle that scalability through
software and the automation that goes in,” Balog said. “It’s a huge
advancement” for research customers that “enables a lot of savings for a lab,”
Gupta added.
Sustainability
is a growing priority for developers of technologies used in the life sciences,
and microarrays are no exception. In fact, it was a central consideration for
the SwiftArrayStudio’s development, Balog said. Some specific steps that the
team took allowed them to reduce plastic use by about 20 percent and introduce
more environmentally friendly reagent formulations. Another change was
replacing the traditional mercury lamp with an LED light source which yields
both environmental and technological benefits, he added. It alleviates disposal
considerations while providing a more stable light source that does not degrade
over time.
Pricing
for the SwiftArrayStudio is determined on a case-by-case basis. The system is
part of Thermo’s broader portfolio, which includes qPCR, capillary
electrophoresis, mass spectrometry, and next-generation sequencing
technologies. “We believe in having the right tool for the job. If you are
doing a GWAS study, microarrays are really well placed for that. But if you
want to look for a smaller number of markers, you probably want to go with
PCR,” Gupta said. Within that landscape, microarrays occupy a distinct space,
he continued, offering a scalable and cost-efficient platform for GWAS and
pharmacogenomic profiling with future applications in methylation and other
omics areas on the roadmap.
Following
an early access program, Thermo is accepting orders for the SwiftArrayStudio.
Installation takes less than two weeks for brand new customers. The company
also provides training to help users run their system. “There [are] a few other
things that we really offer that [are] unique. One, we can create custom arrays
for customers,” Balog said. To help with that, “we’ve been able to implement
some new AI models … that gets the customer up and running much faster.”
📌 Visit Us:
🌐
Website: //statisticsaward.com/
🏆
Nomination:
//statisticsaward.com/award-nomination/
📝
Registration: //statisticsaward.com/award-registration/
Comments
Post a Comment